MapLight Therapeutics Inc Dossier - Source-backed chat

MapLight Therapeutics Inc

MPLTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $9.63Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $535.2M

Enterprise Value $82.1M

Shares Outstanding 42.7M diluted

Next Earnings Date31 Dec 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MapLight Therapeutics is a highly promising clinical-stage biopharmaceutical company targeting multi-billion dollar central nervous system (CNS) markets, specifically schizophrenia and Alzheimer's disease psychosis (ADP). The company's lead asset, ML-007C-MA, is a differentiated M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic designed to maximize central efficacy while minimizing peripheral side effects. With a robust cash position of $395.2 million providing a runway through 2027, and two major Phase 2 clinical readouts (ZEPHYR and IRIS) expected by mid-August 2026, MapLight is positioned at a critical near-term valuation inflection point.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$26.69

High · most bullish analyst$45.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$13.0020%

The Phase 2 ZEPHYR trial fails to show statistically significant efficacy over placebo, or reveals unexpected safety and tolerability concerns (e.g., severe peripheral cholinergic side effects). Additionally, the IRIS trial fails to meet its endpoints. The clinical setbacks severely impair the value of the muscarinic platform, leading to a significant downward re-rating of the stock, leaving the company dependent on its cash balance and early-stage pipeline.

Base CaseCentral scenario

$26.6950%

Matches the consensus mean

The Phase 2 ZEPHYR trial meets its primary endpoint with statistically significant improvements in PANSS scores and a favorable safety profile, validating the M1/M4 muscarinic agonist mechanism. The IRIS trial shows supportive efficacy in autism spectrum disorder. MapLight successfully advances ML-007C-MA into Phase 3 development for schizophrenia while continuing enrollment in the Phase 2 VISTA trial for Alzheimer's disease psychosis, aligning with consensus analyst expectations.

Bull CaseUpside scenario

$45.0030%

The Phase 2 ZEPHYR trial in schizophrenia and IRIS trial in autism spectrum disorder both deliver highly positive topline data by mid-August 2026. ML-007C-MA demonstrates superior efficacy (PANSS reduction) and a cleaner tolerability profile compared to competitors like Cobenfy, positioning it as a best-in-class muscarinic therapy. This triggers rapid progression to Phase 3, potential strategic partnerships with major pharma (such as Sanofi), and drives the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated M1/M4 muscarinic agonist mechanism (ML-007C-MA) designed to optimize pharmacokinetic synchronization and minimize peripheral side effects.
Strong balance sheet with $395.2 million in cash, cash equivalents, and investments as of March 31, 2026, providing a runway through 2027.
Imminent high-impact clinical catalysts with topline Phase 2 data from both the ZEPHYR (schizophrenia) and IRIS (autism) trials expected by mid-August 2026.
Fast Track designation granted by the FDA for ML-007C-MA in Alzheimer's disease psychosis, highlighting the high unmet medical need.

Key Investment Risks

High clinical development risk inherent to central nervous system (CNS) and neuropsychiatric drug candidates.
Intense competition in the muscarinic receptor agonist space, notably from Bristol Myers Squibb's approved drug Cobenfy.
Recent abrupt departure of CFO Vishwas Setia on June 18, 2026, introducing short-term corporate governance and leadership transition risks.

Thesis Invalidation Triggers

Failure of the Phase 2 ZEPHYR trial to meet its primary efficacy endpoint of PANSS total score reduction at Week 5.
Safety or tolerability signals in Phase 2 trials that lead to high discontinuation rates or clinical holds.
Significant acceleration in cash burn rate that prematurely shortens the projected runway through 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.